Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway
about
The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer's disease clinical trials.Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.
P2860
Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 February 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Ex vivo 18O-labeling mass spec ...... al amyloid β clearance pathway
@en
Ex vivo 18O-labeling mass spec ...... l amyloid β clearance pathway.
@nl
type
label
Ex vivo 18O-labeling mass spec ...... al amyloid β clearance pathway
@en
Ex vivo 18O-labeling mass spec ...... l amyloid β clearance pathway.
@nl
prefLabel
Ex vivo 18O-labeling mass spec ...... al amyloid β clearance pathway
@en
Ex vivo 18O-labeling mass spec ...... l amyloid β clearance pathway.
@nl
P2093
P2860
P50
P1476
Ex vivo 18O-labeling mass spec ...... al amyloid β clearance pathway
@en
P2093
Gabriela A N Crespi
Hugo Vanderstichele
Johan Gobom
Luke A Miles
Magnus Gisslén
P2860
P2888
P356
10.1186/S13024-017-0152-5
P50
P577
2017-02-20T00:00:00Z
P6179
1083851362